BCT Knowledge Center Article
Skip Ribbon Commands
Skip to main content
Sign In
{{'GLOBAL_MESSAGE_OR' | translate}}
{{'ELOQUA_BANNER_ACCEPT' | translate}}
{{'ELOQUA_BANNER_DECLINE' | translate}}

Terumo Blood and Cell Technologies Appoints Veerle d’Haenens as General Manager, Cell Therapy Technologies

d’Haenens to leverage portfolio synergies between Therapeutic Systems and Cell Therapy Technologies businesses to drive growth and shape cell therapy ecosystem

Terumo Blood and Cell Technologies, a medical technology company, today announced the promotion of Veerle d'Haenens to General Manager, Global Therapeutic Systems and Cell Therapy Technologies businesses, expanding her role to include growing the company's cell therapy manufacturing solutions.

In this expanded position, d'Haenens will oversee the company's investments and initiatives across these businesses, leveraging their unique synergies and strengths to help the company increase patient access to care. Her goal will be to shape the cell therapy ecosystem to better facilitate the journey of life-saving cells from patient and donor cell collections through cell processing and manufacturing, a holistic approach to help make innovative therapies accessible to more patients. At the same time, she will continue to enhance the therapeutic potential and future development of the company's industry-leading Spectra Optia® Apheresis System, which among other components is used for 94% of white blood cell collections in the U.S. and 67% worldwide.

Veerle's leadership and expertise in commercialization and marketing, as well as her passion for making a difference in healthcare, make her the perfect fit for this expanded role. Under her leadership, we will continue to push the boundaries in cell therapy and ensure novel therapies reach patients around the world.

                                                -Antoinette Gawin, President and Chief Executive Officer of Terumo Blood and Cell Technologies

d'Haenens leads the company's Therapeutic Systems business, which helps improve patients' lives and access to blood and cell therapies by advancing standards of care through therapeutic apheresis, enabling precision medicine for both cell capture and disease mediator removal. Her responsibilities now also encompass the existing Cell Therapy Technologies business, which delivers purpose-built, automated cell manufacturing solutions that reduce manufacturing risks, provide scalability, and support commercialization of cell therapies to meet the growing number of patients globally. These include the Finia® Fill and Finish System — the first-of-its-kind automated solution for the final step of cell therapy manufacturing — and the next-generation Quantum Flex bioreactor platform, launched in late 2022 to allow developers to complete their early process development on the same platform they will use for manufacturing.

I am thrilled to take on this expanded role and continue to make a meaningful impact on patient care and access to life-saving therapies. I look forward to working with our talented team to bring the right therapies at the right time in the patient's treatment journey.-

                                             -Veerle d'Haenens, General Manager, Global Therapeutic Systems and Cell Therapy Technologies 

d'Haenens brings more than 22 years of experience in healthcare, with a passion for making a meaningful contribution to society. She has led cross-functional teams in transforming business models and solutions to meet the changing needs of global customers and patients. She has successfully translated strategy into practical approaches to reach more patients with the company's products, capturing real-time insights from its comprehensive portfolio.

About Terumo Blood and Cell Technologies
Terumo Blood and Cell Technologies is a medical technology company. Our products, software and services enable customers to collect and prepare blood and cells to help treat challenging diseases and conditions. Our employees worldwide believe in the potential of blood and cells to do even more for patients than they do today. This belief inspires our innovation and strengthens our collaboration with customers.

Terumo Blood and Cell Technologies' customers include blood centers, hospitals, therapeutic apheresis clinics, cell collection and processing organizations, researchers and private medical practices. Our customers are based in over 130 countries across the globe. We have 750+ granted patents, with more than 150 additionally pending.

We have global headquarters in Lakewood, Colorado, U.S.A., along with five regional headquarters, seven manufacturing sites and six innovation and development centers across the globe. Terumo Blood and Cell Technologies is a subsidiary of Terumo Corporation (TSE: 4543), a global leader in medical technology. ​

{{'SEARCH_MODAL_TITLE' | translate }}
{{'SEARCH_MODAL_OR' | translate }}

{{'SEARCH_MODAL_BROWSE' | translate }} {{'SEARCH_MODAL_ENLABEL' | translate }}
{{$index+1}}. {{s.label}}